Neogenix Oncology, Inc. (Neogenix) announced today that the Institutional Review Board (IRB) at Conemaugh Valley Memorial Hospital (Memorial Medical Center) in Johnstown, Pennsylvania, has approved the company's protocol for its first Diagnostic Clinical Trial. The study is designed to assess the effectiveness of a panel of Neogenix monoclonal antibodies as diagnostic markers for colorectal and pancreatic cancer. Previous developmental efforts have focused on the role of the lead candidate monoclonal, NPC-1C as a therapeutic agent for these malignancies.
The diagnostic properties of these antibodies will be evaluated in 120 pancreatic and colon cancer patients. The trial is scheduled to begin this month.
"We are pleased to collaborate with Neogenix on this important study," said Principal Investigator Ibrahim Sbeitan, M.D. "We are hopeful that this trial (Detection and Assessment of the Prognostic Value of Immunologic and Molecular Biomarkers in the Serum of Patients with Solid Tumors) will provide us with new insights into how we can improve our ability to make an accurate diagnosis of solid tumors much earlier in the disease process, thus giving patients a greater opportunity for an improved outcome."
"Since their discovery, we have observed that our antibodies have both therapeutic and diagnostic properties," said Neogenix President and Chief Medical Officer, Philip M. Arlen, MD. "While our efforts thus far have focused on developing the therapeutic potential for our first antibody, NPC-1C, the initiation of this trial marks the expansion of our focus to include diagnostics. Our goal is to develop a new generation of serum diagnostics which will make an important contribution to the earlier diagnosis and improvement in the management of a number of common malignancies."
About Neogenix Oncology, Inc.
Founded in 2004 and headquartered in Great Neck, NY, Neogenix Oncology, Inc., is a research-driven biopharmaceutical company that develops and commercializes innovative therapeutics and diagnostics for the management of serious and difficult to treat cancers. Neogenix's pipeline is derived in part from the Hollinshead library of clinically tested vaccines, with the potential to develop products for a wide range of cancers, including pancreas, colorectal, prostate, lung, ovarian, squamous, and others. The company conducts its research and development work in its laboratories in Great Neck, NY and in Rockville, MD. For more information, please visit the company's website at neogenixoncology.
About Memorial Medical Center
Conemaugh Health System is the largest health care provider in west central Pennsylvania, serving families across 11 counties through our network of hospitals, physician offices, specialty clinics and other patient-focused programs.
Memorial Medical Center, the flagship hospital of the Conemaugh Health System, has been recognized with the Health Grades 2008 Distinguished Hospital Award for Clinical Excellence. This ranks Memorial in the top 5% of all hospitals in the nation for overall clinical performance.
This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.
Neogenix Oncology, Inc
Комментариев нет:
Отправить комментарий